EUCTR2008-004842-10-GB进行中（未招募）不适用
A phase II, multinational, multicentre, double blind, double dummy, randomised, 5-way cross-over, placebo and active controlled clinical study to test the non-inferiority of a single dose of CHF 1535 (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg dry powder) via NEXT™ DPI 1 or 4 inhalations versus CHF 1535 (beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg) pMDI with HFA-134a propellant 1 or 4 puffs on FEV1 AUC0-12h in partly controlled adult asthmatic patients
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following inclusion criteria to be eligible for enrolment into the study:
- •1. Patient’s written informed consent obtained prior to any study-related procedures. Patients incapable of giving consent personally or vulnerable patients (except women of childbearing potential with acceptable method of contraception) cannot be included in the study.
- •2. Outpatient male or female aged = 18 years.
- •3. Evidence for partly controlled” asthma in the 2 weeks before the screening visit (during the pre-screening period) according to the Classification of Asthma Severity and Levels of Asthma Control of the Global Strategy for Asthma Management and Prevention (GINA guidelines 2006) i.e. one or more of the following: - daytime symptoms more than twice / week; - any limitations of activities or nocturnal symptoms / awakening; - need for reliever/rescue treatment more than twice / week.
- •4. Daily dose of previous inhaled corticosteroids (ICS) treatment at the screening visit:
- •a. = 2000 µg of CFC BDP or BDP non-extrafine”
- •b. = 800 µg of BDP extrafine” HFA
- •c. = 1600 µg of budesonide
- •d. = 1000 µg of fluticasone
- •e. = 2000 µg of flunisolide
- •f. = 1200 µg of mometasone
- •g. = 1280 µg of ciclesonide
- •5. Forced expiratory volume in the first second (FEV1) = 60% and = 90% of the predicted normal values at the screening visit.
- •6. A documented positive response to the reversibility test at the screening visit, defined as ?FEV1 = 12% and = 200 mL over baseline, 30 minutes after 400 µg salbutamol pMDI (ATS/ERS taskforce 2005).
- •7. Patients free of long-acting beta ?2-agonists (LABAs) treatment for at least 2 weeks before the screening visit.
- •8. Patients free of short-acting ?beta 2-agonists (SABAs) treatment for at least 6 hours before the screening visit.
- •9. Non-smokers or ex-smokers with a cumulative tobacco exposure less than 5 pack-years and who have stopped smoking for more than 1 year (pack-year: number of cigarettes smoked per day multiplied by the number of years of smoking divided by 20).
- •10. A cooperative attitude and ability to be trained in the proper use of a pMDI and a DPI.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant or lactating women or all women physiologically capable of becoming pregnant UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL or are using one or more of the following highly effective and acceptable methods of contraception.
- •a. surgical sterilization (e.g. bilateral tubal ligation, hysterectomy)
- •b. hormonal contraception (implantable, injectable, patch, oral)
- •c. double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)
- •A urine pregnancy test will be performed at screening in women of childbearing potential.
- •2. Significant seasonal variation in asthma or asthma occurring only during episodic exposure to an allergen or a chemical sensitizer.
- •3. History of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma exacerbation in Intensive Care Unit) within 1 year before screening.
- •4. Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening visit.
- •5. Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (updated 2006).
- •6. History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency.
- •7. Diagnosis of restrictive lung disease.
- •8. Patients treated with oral or parenteral corticosteroids in the previous 8 weeks (12 weeks for parenteral depot corticosteroids) before screening visit.
- •9. Intolerance or contra-indication to treatment with beta 2-agonists and/or inhaled corticosteroids.
- •10. Allergy, sensitivity or intolerance to study drugs or excipients.
- •11. Patients who received any investigational new drug, or participated in clinical study within the last 8 weeks before the screening. The patients cannot participate in another clinical study as the same time as the present study.
- •12. Subjects unlikely to comply with the study protocol or unable to understand the nature and scope of the study but also the possible benefits or unwanted effects of the study treatments.
- •13. Significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, or any laboratory abnormality indicative of a significant underlying condition, that may interfere with patient’s safety, compliance, or study evaluations, according to the Investigator’s opinion.
研究者
相似试验
进行中（未招募）
不适用
A study to compare the single administration of a product called CHF 1535 (two medicines together for the treatment of asthma) and the same two single medicines, measuring the air contained in the lungs in asthmatic childreAsthmaEUCTR2011-002060-24-PLChiesi Farmaceutici SpA100
进行中（未招募）
不适用
A phase II, multinational, multicentre, double blind, double dummy, randomised, 5-way cross-over, placebo and active controlled clinical study to test the non-inferiority of a single dose of CHF 1535 (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg dry powder) via NEXT? DPI 1 or 4 inhalations versus CHF 1535 (beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg) pMDI with HFA-134a propellant 1 or 4 puffs on FEV1 AUC0-12h in partly controlled adult asthmatic patients - NDPartly controlled adult asthmatic patientsMedDRA version: 9.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2008-004842-10-ITCHIESI65
进行中（未招募）
不适用
A study to compare the single administration of a product called CHF 1535 (two medicines together for the treatment of asthma) and the same two single medicines, measuring the air contained in the lungs in asthmatic childreasthmaEUCTR2011-002060-24-Outside-EU/EEAChiesi Farmaceutici SpA60
进行中（未招募）
1 期
A phase II, multinational, multicentre, double blind, double dummy, randomised, 5-way cross-over, placebo and active controlled clinical study to test the non-inferiority of a single dose of CHF 1535 (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg dry powder) via NEXT™ DPI 1 or 4 inhalations versus CHF 1535 (beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg) pMDI with HFA-134a propellant 1 or 4 puffs on FEV1 AUC0-12h in partly controlled adult asthmatic patientsEUCTR2008-004842-10-FRChiesi Farmaceutici S.p.A.65
进行中（未招募）
不适用
A 3 month Study of Darapladib to Treat Diabetic Macular Edema (DME).Diabetic macular edema with centre involvementMedDRA version: 14.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disordersEUCTR2011-002944-28-DEGlaxoSmithKline Research & Development Limited54